research chemical comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-06-12. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
Zopiclone is used for the short-term treatment of insomnia where difficulty with sleep initiation or sleep maintenance are prominent symptoms. Long-term use is not recommended, as tolerance, dependence, and addiction can occur. Benzodiazepine-like drugs decrease sleep latency by 10 to 20 minutes. However, no benzodiazepine-like drug has shown clinically significant increase in total sleep time which is defined as at least 30 minutes. Tolerance develops within days to weeks. The risk of developing tolerance with benzodiazepine-like drugs is comparable to benzodiazepines. Zopiclone is recommended to be taken at the lowest effective dose, with a duration of 2–3 weeks for short-term insomnia. Use of zopiclone more than 4 weeks is not recommended. Caution must be taken when the compound is used in conjunction with benzodiazepines, sedatives or other drugs affecting the central nervous system. One low-quality study found that zopiclone is ineffective in improving sleep quality or increasing sleep time in shift workers. Cognitive behavioral therapy has been found to be superior to zopiclone in the treatment of insomnia and has been found to have lasting effects on sleep quality for at least a year after therapy.
Raffi Berg is the Middle East editor of the BBC News website; graduated in modern and medieval history from the London School of Economics; was student of Jewish and Israel studies at the Hebrew University of Jerusalem; author of Red Sea Spies: The True Story of Mossad's Fake Diving Resort (Icon Books, 2020) Lionel Blue, rabbi and journalist Amber de Botton, head of UK news at ITV News; was previously head of politics at ITV and deputy head of politics at Sky News, after starting career as a parliamentary reporter; currently Prime Minister Rishi Sunak's director of communications. Julian Borger; journalist and non-fiction writer; world affairs editor at The Guardian. He was a correspondent in the United States, Eastern Europe, the Middle East and the Balkans and covered the Bosnian War for the BBC. Borger is a contributor to the Center on International Cooperation, a foreign policy think tank based at New York University that works to enhance multilateral responses to global problems, including conflict, humanitarian crises, and recovery; international security challenges, including weapons proliferation and the changing balance of power; resource scarcity and climate change.
=== Cancer resistance === Dermal macrophages can adjust their phenotypes to increase or suppress skin inflammation by different gene profiles, which can slow down the development of certain cancers. For instance, they can suppress the development of basal cell carcinoma. Basal cell carcinoma is induced by mutations in PTCH1, a tumour-suppressor protein, leading to uncontrollable cell growth. In rodents, there is increased growth of basal cell carcinoma and loss of normal cells without the presence of macrophages. Therefore, dermal macrophages are associated with cancer defence.
Sources: en.wikipedia.org
=== Paraphimosis and other conditions === In some cases the foreskin may become swollen as a result of paraphimosis (foreskin trapped behind the glans) or other conditions such as severe balanitis. Should reduction of the swelling by conservative methods be unsuccessful, a dorsal slit is a common intervention of choice since circumcision is almost always excluded in such cases. While it was formerly recommended that circumcision be subsequently performed once the originating condition has subsided, this appears to be no longer the case.
== Selected publications == Tiwari, V. Jin, Byungchang; Sun, Olivia; LopezGonzalez, Edwin D. J.; Chen, Min-Hsuan; Wu, Xiwei; Shah, Hardik; Zhang, Andrew; Herman, Mark A.; Spracklen, Cassandra N.; Goodman, Russell P.; Brenner, Charles (November 2025). "Glycerol-3-phosphate activates ChREBP, FGF21 transcription and lipogenesis in citrin deficiency". Nature Metabolism. 7 (11): 2284–2299. doi:10.1038/s42255-025-01399-3. ISSN 2522-5812. PMC 12638245 Brenner, C (2022-09-22). "Sirtuins are not conserved longevity genes". Life Metabolism (2): 122–133. doi:10.1093/lifemeta/loac025. ISSN 2755-0230. PMC 10081735. PMID 37035412. Brenner, C (January 2022). "Viral infection as an NAD+ battlefield". Nature Metabolism. 4 (1): 2–3. doi:10.1038/s42255-021-00507-3. ISSN 2522-5812. PMC 10155260. PMID 34980922. S2CID 245654307. Heer, CD; Sanderson, DJ; Voth, LS; Alhammad, YMO; Schmidt, MS; Trammell, SAJ; Perlman, S; Cohen, MS; Fehr, AR; Brenner, C (2020-10-13). "Coronavirus infection and PARP expression dysregulate the NAD Metabolome: an actionable component of innate immunity". Journal of Biological Chemistry. 295 (52): 17986–17996. doi:10.1074/jbc.RA120.015138. PMC 7834058. PMID 33051211. Vaur, P; Brugg, B; Mericskay, M; Li, Z; Schmidt, M S.; Vivien, D; Orset, C; Jacotot, E; Brenner, C (December 2017). "Nicotinamide riboside, a form of vitamin B3, protects against excitotoxicity-induced axonal degeneration". FASEB Journal. 31 (12): 5440–5452. doi:10.1096/fj.201700221RR. ISSN 1530-6860. PMID 28842432.
== History == Streptomycin was first isolated on October 19, 1943, by Albert Schatz, a PhD student in the laboratory of Selman Abraham Waksman at Rutgers University in a research project funded by Merck and Co. Waksman and his laboratory staff discovered several antibiotics, including actinomycin, clavacin, streptothricin, streptomycin, grisein, neomycin, fradicin, candicidin, and candidin. Of these, streptomycin and neomycin found extensive application in the treatment of numerous infectious diseases. Streptomycin was the first antibiotic cure for tuberculosis (TB). In 1952 Waksman was the recipient of the Nobel Prize in Physiology or Medicine in recognition "for his discovery of streptomycin, the first antibiotic active against tuberculosis". Waksman was later accused of playing down the role of Schatz who did the work under his supervision, claiming that Elizabeth Bugie had a more important role in its development. Schatz sued both Dr. Waksman and the Rutgers Research and Endowment Foundation, wanting to be given credit as co-discover and to receive the royalties for the streptomycin. By the end of the settlement, Waksman would receive a 10% royalty, while Schatz got 3% and compensation for his missed royalties. The rest of the lab shared the remaining 7% of the royalties, in which Bugie received 0.2%. Bugie was pursuing a master's degree in Waksman's lab at Rutgers University at this time. Prior to this, she received her bachelor's degree in microbiology at New Jersey College for Women.
Sources: en.wikipedia.org
== RSKSOP-175 analysis of petroleum gases == A widely used methods for headspace analysis is described by the United States Environmental Protection Agency (USEPA) was developed as a "high quality, defendable, and documented way to measure" methane, ethane, and ethene, RSKSOP-175 is a standard operating procedure (SOP) and an unofficial method employed by the USEPA to detect and quantify dissolved gases in water. This method has been used to quantify dissolved hydrogen, methane, ethylene, ethane, propane, butane, acetylene, nitrogen, nitrous oxide, and oxygen. The method uses headspace gas injected into a gas chromatographic column (GC) to determine the original concentration in a water sample.
In October 2022, 777 Partners bought a minority stake in Melbourne Victory FC of the Australian A-League Men for AU$8.7 million. The following January, the club's shareholders voted in favor of allowing 777 Partners to secure up to 70% over the next five years, in exchange for AU$30 million in investment. The voluntary administration of 777 Partners' Australian airline Bonza in 2024 meant that Melbourne Victory were sponsored by AIA Group for the playoffs that year, before a long-term deal with Turkish Airlines could begin in 2025.
As a response, Mexico saw an increase in violence caused by drug trafficking. The corruption cartels created resulted in distrust of government by the Mexican public. This distrust became more prominent after the collapse of the PRI party. In response, the presidents of Mexico, in the late twentieth century and early twenty-first century, implemented several different programs relating to law enforcement and regulation. In 1993, President Salinas created the National Institute for the Combat of Drugs in Mexico. From 1995 to 1998, President Zedillo established policies regarding increased punishment of organized crime, allowing "[wire taps], protected witnesses, covert agents and seizures of goods", and increasing the quality of law enforcement at the federal level. From 2001 to 2005, President Vicente Fox created the Federal Agency of Investigation. These policies resulted in the arrests of major drug-trafficking bosses:
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.